104 related articles for article (PubMed ID: 18606580)
1. Binding of the doxorubicin-lactosaminated human albumin conjugate to HCC cells is mediated by the drug moieties.
Baglioni M; Fiume L; Bolondi L; Farina C; Kratz F; Di Stefano G
Dig Liver Dis; 2008 Dec; 40(12):963-4. PubMed ID: 18606580
[No Abstract] [Full Text] [Related]
2. Doxorubicin coupled to lactosaminated albumin: Effects on rats with liver fibrosis and cirrhosis.
Di Stefano G; Fiume L; Domenicali M; Busi C; Chieco P; Kratz F; Lanza M; Mattioli A; Pariali M; Bernardi M
Dig Liver Dis; 2006 Jun; 38(6):404-8. PubMed ID: 16595196
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin coupled to lactosaminated human albumin: a hepatocellular carcinoma targeted drug.
Fiume L; Baglioni M; Bolondi L; Farina C; Di Stefano G
Drug Discov Today; 2008 Nov; 13(21-22):1002-9. PubMed ID: 18755287
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine.
Fiume L; Bolondi L; Busi C; Chieco P; Kratz F; Lanza M; Mattioli A; Di Stefano G
J Hepatol; 2005 Oct; 43(4):645-52. PubMed ID: 16023760
[TBL] [Abstract][Full Text] [Related]
5. A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation grade.
Di Stefano G; Fiume L; Baglioni M; Bolondi L; Busi C; Chieco P; Kratz F; Manaresi F; Pariali M
Liver Int; 2006 Aug; 26(6):726-33. PubMed ID: 16842330
[TBL] [Abstract][Full Text] [Related]
6. Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin.
Di Stefano G; Fiume L; Baglioni M; Busi C; Chieco P; Kratz F; Mattioli A
Eur J Pharm Sci; 2007 Feb; 30(2):136-42. PubMed ID: 17218086
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin coupled to lactosaminated albumin: enhanced drug levels in rat hepatocarcinomas.
Di Stefano G; Busi C; Fiume L; Chieco P; Pariali M
Dig Liver Dis; 2006 Apr; 38(4):284-5. PubMed ID: 16364702
[No Abstract] [Full Text] [Related]
8. Doxorubicin coupled to lactosaminated albumin: effect of heterogeneity in drug load on conjugate disposition and hepatocellular carcinoma uptake in rats.
Di Stefano G; Fiume L; Baglioni M; Busi C; Bolondi L; Farina C; Mori F; Chieco P; Pariali M; Kratz F; Molin L; Salmaso S; Caliceti P
Eur J Pharm Sci; 2008 Feb; 33(2):191-8. PubMed ID: 18201877
[TBL] [Abstract][Full Text] [Related]
9. Lactosaminated human albumin, a hepatotropic carrier of drugs.
Fiume L; Di Stefano G
Eur J Pharm Sci; 2010 Jul; 40(4):253-62. PubMed ID: 20403430
[TBL] [Abstract][Full Text] [Related]
10. A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells.
Toita R; Murata M; Abe K; Narahara S; Piao JS; Kang JH; Hashizume M
Chem Commun (Camb); 2013 Aug; 49(67):7442-4. PubMed ID: 23860596
[TBL] [Abstract][Full Text] [Related]
11. Improvement of pharmacokinetics and antitumor activity against human hepatoma cell line by using adriamycin-entrapped stealth liposomes.
Shimizu H; Kumai K; Uyama I; Shibata S; Tagawa T; Nagaike K; Yasuda T; Kitajima M; Tadakuma T
J Surg Oncol; 1996 Jul; 62(3):186-93. PubMed ID: 8667626
[TBL] [Abstract][Full Text] [Related]
12. Examination of fabrication conditions of acrylate-based hydrogel formulations for doxorubicin release and efficacy test for hepatocellular carcinoma cell.
Bayramoglu G; Gozen D; Ersoy G; Ozalp VC; Akcali KC; Arica MY
J Biomater Sci Polym Ed; 2014; 25(7):657-78. PubMed ID: 24580096
[TBL] [Abstract][Full Text] [Related]
13. Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems.
Dubbelboer IR; Lilienberg E; Ahnfelt E; Sjögren E; Axén N; Lennernäs H
Ther Deliv; 2014 Apr; 5(4):447-66. PubMed ID: 24856170
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of doxorubicin coupled to lactosaminated albumin on rat hepatocellular carcinomas evaluated by ultrasound imaging.
Di Stefano G; Fiume L; Baglioni M; Bolondi L; Chieco P; Kratz F; Pariali M; Rubini G
Dig Liver Dis; 2008 Apr; 40(4):278-84. PubMed ID: 18054847
[TBL] [Abstract][Full Text] [Related]
15. Liver-targeted doxorubicin: effects on rat regenerating hepatocytes.
Di Stefano G; Derenzini M; Kratz F; Lanza M; Fiume L
Liver Int; 2004 Jun; 24(3):246-52. PubMed ID: 15189276
[TBL] [Abstract][Full Text] [Related]
16. Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumors.
Di Stefano G; Fiume L; Bolondi L; Lanza M; Pariali M; Chieco P
Liver Int; 2005 Aug; 25(4):854-60. PubMed ID: 15998437
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of non-islet cell tumor hypoglycemia in hepatocellular carcinoma with doxorubicin.
Kampitak T
Cancer Chemother Pharmacol; 2008 Oct; 62(5):929-30. PubMed ID: 18278497
[No Abstract] [Full Text] [Related]
18. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma.
Mi JX; Wang GF; Wang HB; Sun XQ; Ni XY; Zhang XW; Tang JM; Yang DJ
Acta Pharmacol Sin; 2008 Dec; 29(12):1467-77. PubMed ID: 19026166
[TBL] [Abstract][Full Text] [Related]
19. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Gramantieri L; Giovannini C; Veronese A; Ferracin M; Sabbioni S; Calin GA; Grazi GL; Croce CM; Tavolari S; Chieco P; Negrini M; Bolondi L
Cancer Res; 2009 Jul; 69(14):5761-7. PubMed ID: 19584283
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin coupled to lactosaminated human albumin remains confined within mouse liver cells after the intracellular release from the carrier.
Di Stefano G; Kratz F; Lanza M; Fiume L
Dig Liver Dis; 2003 Jun; 35(6):428-33. PubMed ID: 12868680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
